The researchers found that 358,075 of 1.7 million individuals were dispensed antidepressants, and 8,495 of the 24,783 ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive results from the Phase Ib ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of incretin mimetic medicines for the treatment of Type 2 ...

Viking Therapeutics (VKTX) stock falls after Roche (RHHBY) posted promising Phase 1 results for its experimental obesity ...

One in eight adults (12 percent) say they have ever taken a glucagon-like peptide-1 receptor agonist (GLP-1 RA) and 6 percent ...

A recent clinical trial of Wegovy showed that 17 percent of patients on the drug left the trial because of side effects.

One in eight adults say they have ever taken a GLP-1 RA and 6 percent say they are currently using one, according to study results.

Newly released clinical trial data on the GLP-1 agonist drug Wegovy found that weight loss was sustained for up to four years ...

Other findings from the latest Kaiser Family Foundation Health Tracking Poll shed light on public awareness, use, and ...

Only about half of folks with Type 2 diabetes have their blood sugar under control and regularly achieve an A1C of 7% or less. That puts them at increased risk ...

The current breakthrough weight-loss drugs are only the beginning, according to Danish researchers hard at work on a new ...